piperacillin has been researched along with Health Care Associated Infection in 157 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (5.73) | 18.7374 |
| 1990's | 22 (14.01) | 18.2507 |
| 2000's | 68 (43.31) | 29.6817 |
| 2010's | 55 (35.03) | 24.3611 |
| 2020's | 3 (1.91) | 2.80 |
| Authors | Studies |
|---|---|
| Cornaglia, G; Koncan, R; Mazzariol, A; Roelofsen, E; Voss, A | 1 |
| Caniça, M; Ferreira, E; Leitão, J; Manageiro, V; Mendonça, N | 1 |
| Bonomo, RA; Endimiani, A; Hujer, AM; Hujer, KM; Luzzaro, F; Mantengoli, E; Migliavacca, R; Pagani, L; Rossolini, GM; Toniolo, A | 1 |
| Avlami, A; Daikos, GL; Katsilambros, N; Kosmidis, C; Petrikkos, G; Psychogiou, M; Stefanou, I; Tassios, PT; Vasilakopoulou, A | 1 |
| Castanheira, M; Jones, RN; Mendes, RE; Sader, HS; Toleman, MA; Walsh, TR | 1 |
| Grosso, F; Peixe, L; Quinteira, S; Ramos, H | 1 |
| Bouza, E; Cercenado, E; Coll, P; Gutiérrez, O; Juan, C; Navarro, F; Oliver, A; Pérez, JL | 1 |
| Carrillo, B; Esparza-Ahumada, S; Garza-Ramos, U; Hernández, E; Jones, RN; Morfin-Otero, R; Rodriguez-Noriega, E; Sader, HS; Sanchez, A; Silva-Sanchez, J | 1 |
| Badur, S; Cagatay, AA; Carrër, A; Eraksoy, H; Nordmann, P; Poirel, L | 1 |
| Hsueh, PR; Huang, YT; Liao, CH; Lin, HY; Liu, CY; Yen, LC | 1 |
| Karlowsky, JA; Laing, NM; Zhanel, GG | 1 |
| Afif, C; Bagattini, M; Daoud, Z; Di Popolo, A; Khan, AU; Triassi, M; Vitale, D; Zarrilli, R | 1 |
| Acosta, J; Chaves, F; Juan, C; Oliver, A; Otero, JR; Sanz, F; Viedma, E; Zamorano, L | 1 |
| De Luca, F; Docquier, JD; Ide, L; Nordmann, P; Poirel, L; Rossolini, GM; Verlinde, A | 1 |
| Ge, Y; Juan, C; Moya, B; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Bautista, J; Beique, L; Cayen, J; Choi, K; Comeau, JL; Conly, J; Dalton, B; Delport, J; Dhami, R; Embree, J; Émond, Y; Evans, G; Frenette, C; Fryters, S; Happe, J; Katz, K; Kibsey, P; Langley, JM; Lee, BE; Lefebvre, MA; Leis, JA; McGeer, A; McKenna, S; Neville, HL; Pelude, L; Rudnick, W; Science, M; Slayter, K; Suh, KN; Thirion, DJG; Tse-Chang, A; Weiss, K | 1 |
| Autmizguine, J; Kassir, N; Lavigne, J; Litalien, C; Théorêt, Y; Thibault, C | 1 |
| Arshad, U; Beer, R; Dorn, C; Fuhr, U; Helbok, R; Kofler, M; Kratzer, A; Taubert, M; Ullah, S; Zeitlinger, M | 1 |
| Agic, A; Milicic, D; Pasalic, M; Samardzic, J; Skoric, B | 1 |
| Alp, E; Çetin, M; Elmali, F; Kaynar, L; Kürkçüoglu, CA; Metan, G; Yozgat, N | 1 |
| Clark, R; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CP; Kelly, MS; Ku, LC; Salerno, S; Smith, PB | 1 |
| Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y | 1 |
| Huang, YC; Lin, YT; Wang, FD | 1 |
| Arnaud, E; Larcher, R; Lavigne, JP; Pantel, A; Sotto, A | 1 |
| Gemperli, R; Gomez, DS; Levin, AS; Machado, AS; Oliveira, MS; Sanches, C; Santos, SRCJ; Silva Junior, CVD | 1 |
| Dolff, B; Harder, S; Hogardt, M; Keiner, N; Kempf, VAJ; Kessel, J; Reinheimer, C; Stephan, C; Wichelhaus, T; Wieters, I | 1 |
| Oda, K; Ota, K; Sakamoto, N; So, M; Suzuki, T | 1 |
| Castanheira, M; Duncan, LR; Flamm, RK; Sader, HS | 1 |
| Hao, D; Hu, Z; Liu, X; Sun, T; Tian, H; Wang, T; Wang, X | 1 |
| Azam, N; Cherkaoui, A; Fischer, A; Riat, A; Schrenzel, J | 1 |
| Li, J; Ma, W; Sun, S; Wang, D; Yu, C | 1 |
| Ciccia, M; Dallolio, L; Fabbri, G; Farruggia, P; Panico, M; Sandri, F; Suzzi, R | 1 |
| Choi, EH; Lee, HJ; Lee, J; Oh, CE | 1 |
| Hsueh, PR; Lee, YT; Tsao, SM | 1 |
| Feizabadi, MM; Ghodousi, A; Haeili, M; Nomanpour, B; Omrani, M | 1 |
| Fuchita, H; Hamaguchi, S; Honda, T; Hotta, T; Isobe, T; Iwamoto, S; Karino, F; Koba, N; Kuraki, T; Miura, K; Nishikawa, E; Ohe, M; Okimoto, T; Sutani, A; Tada, M; Takeyama, H; Tsubata, Y | 1 |
| Dong, WL; Lü, Y; Wang, DH; Xia, R; Yan, Z; Yang, Y | 1 |
| Chang, SW; Chen, PR; Kuo, HY; Liou, ML; Liu, CC; Pien, CJ; Yeh, HW | 1 |
| Bosnak, VK; Karaoglan, I; Mete, AO; Namiduru, M; Zer, Y | 1 |
| Ben Khalifa, S; Daiki, M; Fekih Hassen, A | 1 |
| Chan, MC; Chang, FY; Lee, Y; Lin, JC; Lin, TY; Yang, YS; Yeh, KM | 1 |
| Castanheira, M; Farrell, DJ; Jones, RN; Mills, JC | 1 |
| Hamaguchi, S; Ikawa, K; Ishihara, N; Karino, F; Kuraki, T; Miura, K; Morikawa, N; Moriyama, H; Nishimura, N; Sutani, A | 1 |
| Du, Y; Guo, W; He, J; He, Q; Wang, Z; Wei, M; Wu, C; Yang, Z | 1 |
| Cattoir, V; Dargère, S; Daurel, C; de La Blanchardière, A; Guérin, F; Saint-Lorant, G; Verdon, R | 1 |
| Chen, R; Qian, CY; Qian, Q; Sun, MR; Wang, LY; Wang, ML; Zou, SL | 1 |
| Hirose, Y; Ishikawa, H; Kamata, K; Kanemoto, K; Shiotani, S; Suzuki, H; Suzuki, M; Tokuda, Y | 1 |
| Nicolau, DP; Sutherland, CA | 1 |
| Havey, TC; Hull, MW; Leung, V; Romney, MG | 1 |
| Duane, TM; Kikhia, RM; Ober, J; Tessier, JM; Wolfe, LG | 1 |
| Alicino, C; Di Bella, A; Durando, P; Fontana, S; Gritti, PR; Marchese, A; Orsi, A; Parodi, MC; Ricci, ML; Rota, MC; Scaturro, M; Tinteri, C | 1 |
| Acosta-García, H; Alfaro-Lara, ER; Bautista-Paloma, FJ; Beltrán-García, M; Cotrina-Luque, J; Gil-Navarro, MV; Luque-Márquez, R | 1 |
| Badal, RE; Cao, B; Chen, S; Chu, Y; Duan, Q; Feng, X; Gui, B; Hu, B; Hu, Z; Huang, W; Kong, H; Liao, K; Luo, Y; Ni, Y; Shao, H; Su, J; Sun, Z; Wang, Y; Wu, A; Xu, Y; Yang, Q; Yu, Y; Zhang, H; Zhang, S | 1 |
| Arakawa, Y; Fujita, A; Jin, W; Kimura, K; Mikamo, H; Suematsu, H; Wachino, J; Yamada, K; Yamagishi, Y; Yokoyama, S | 1 |
| Becker, K; Bletz, S; Böking, T; Harmsen, D; Kipp, F; Mellmann, A; Prior, K; Schultes, A | 1 |
| Bao, H; Lv, Y; Wang, D; Xue, J; Yan, Z | 1 |
| Carvalheira, A; Casquete, R; Silva, J; Teixeira, P | 1 |
| Anupurba, S; Banerjee, T | 1 |
| Alberg, T; Blix, HS; Eriksen, HM; Holen, Ø; Neteland, MI; Smith, I | 1 |
| Friedland, I; Kaniga, K; Ketter, N; Lee, M; Lobo, SM; Niederman, M; Prokocimer, P; Réa-Neto, A; Schroeder, E | 1 |
| Aldeyab, MA; Bailie, R; Elshibly, SM; Hanley, J; Hughes, CM; Kearney, MP; McDowell, DA; McElnay, JC; McMahon, MA; Scott, MG | 1 |
| Alquezar, A; Castro, P; Codina, C; Delgado, E; Marco, F; Martí, S; Martínez, JA; Mensa, J; Nicolás, JM; Soriano, A; Torres, A; Trilla, A; Vila, J | 1 |
| Akinci, E; Balaban, N; Baran, G; Bodur, H; Cevik, MA; Erbay, A; Onguru, P | 1 |
| Simon, A; Wolf, MF | 1 |
| Cotter, M; Crowley, B; O Connell, N; Roche, C | 1 |
| Restrepo, MI | 1 |
| Bahram, F; Emaneini, M; Fatolahzadeh, B; Feizabadi, MM; Mehdi, FM; Mohammad, E; Morovat, T; Setareh, S; Soroush, S; Taherikalani, M | 1 |
| Drusano, GL; Lodise, TP; Patel, N; Scheetz, MH | 1 |
| De Waele, JJ; Deja, M; Diaz, E; Guven, M; Koulenti, D; Lisboa, T; Mañez, R; Martin-Loeches, I; Putensen, C; Rello, J; Ulldemolins, M | 1 |
| Bai, H; He, G; Hou, Z; Jia, M; Luo, X; Ma, X; Meng, J; Wang, H; Wang, R; Yu, J | 1 |
| Chung, DR; Ha, YE; Joo, EJ; Kang, CI; Kang, SJ; Lee, NY; Park, SY; Peck, KR; Song, JH | 1 |
| Altunsoy, A; Aypak, C; Azap, A; Balık, I; Ergönül, Ö | 1 |
| Mikamo, H; Miura, Y; Ohki, E; Terada, M; Umemura, T; Yamagishi, Y | 1 |
| Baykan, M; Demircili, ME; Feyzioğlu, B; Özdemir, M; Pekcan, S; Pirinç, Ş; Taşbent, FE | 1 |
| Anderson, DJ; Bennett, KM; Dotson, TL; Sarraf-Yazdi, S; Sharpe, M; Vaslef, SN | 1 |
| Hsueh, PR; Lee, YJ; Lin, YC; Liu, HY; Wu, HH | 1 |
| Butterfield, JM; Drusano, GL; Felton, TW; Hope, WW; Kwa, AL; Lodise, TP; Lomaestro, BM | 1 |
| Arnold, HM; Hampton, NB; Hoban, A; Hoffmann, J; Hollands, JM; Juang, PH; Kollef, MH; McCormick, S; Micek, ST; Reichley, RM; Skrupky, LP; Smith, JR | 1 |
| Imamura, Y; Izumikawa, K; Kakeya, H; Kohno, S; Kurihara, S; Miyazaki, T; Morinaga, Y; Nakamura, S; Tsukamoto, M; Yamamoto, Y; Yanagihara, K; Yasuoka, A | 1 |
| Dul, MJ; Hoyen, C; Salvator, A; Toltzis, H; Toltzis, P; Walsh, M; Zetts, L | 1 |
| Brun-Buisson, C | 1 |
| Barr, J; Flavin, KE; Fowler, RA; Gould, MK; Parsonnet, J; Weinacker, AB | 1 |
| Chen, MJ; Wang, H | 1 |
| Alos, JI; Gomez-Garces, JL; Hernaiz, C; Picardo, A | 1 |
| Daschner, FD; Frank, U; Mutter, J; Schmidt-Eisenlohr, E | 1 |
| Donskey, CJ; Harmoinen, J; Helfand, MS; Koski, P; Lindevall, K; Pultz, NJ; Stiefel, U | 1 |
| Bardenstein, R; Flidel-Rimon, O; Friedman, S; Gradstein, S; Shinwell, ES | 1 |
| Arango, C; Bantar, C; Coassolo, MA; Duret, F; Fiorillo, A; Franco, D; Gomez, H; Heft, C; Krayeski, M; Oliva, ME; Salamone, F; Vesco, E | 1 |
| Ahern, JW; Alston, WK | 1 |
| Allaouchiche, B; Boselli, E; Breilh, D; Cannesson, M; Chassard, D; Rimmelé, T; Saux, MC; Xuereb, F | 1 |
| Apfalter, P; Berger, A; Kretzer, V; Pollak, A; Rohrmeister, K; Zaknun, D | 1 |
| Danziger, LH; Drusano, GL; Lodise, TP; Lomaestro, B; Rodvold, KA | 1 |
| Bangsberg, DR; Chambers, HF; Charlebois, ED; Pang, S; Perdreau-Remington, F; Winston, LG | 1 |
| Ackermann, T; Bertram, N; Buck, C; Derendorf, H; Paar, WD; Sauerbruch, T | 1 |
| Daschner, FD; Ebner, W; Heininger, A; Meyer, E; Rüden, H; Schwab, F | 1 |
| Kuti, JL; Nicolau, DP; Sun, HK | 1 |
| Carmeli, Y; Flores, EL; Lin, MY; Sreeramoju, P; Tolentino, J; Weber, SG; Zumsteg, J | 1 |
| Bassoul, B; Causse, L; Dareau, S; Delire, V; Eledjam, JJ; Gros, T; Javitary, W | 1 |
| Das, BK; Dhawan, B; Kapil, A; Mohanty, S; Singhal, R; Sood, S | 1 |
| Cooper, A; Joshi, M; Kassira, W; McCarthy, M; Metzler, M; Olvey, S | 1 |
| Gibbs, L; Guglielmo, BJ; Jacobs, RA; McCulloch, CE; Mendez, MN; Winston, L | 1 |
| Rice, LB | 1 |
| Leitner, E; Lode, H; Schmitt, DV; Welte, T | 1 |
| Choudhri, S; Herrington, J; Malangoni, MA; Pertel, P; Song, J | 1 |
| de Cueto, M; Hernández, JR; Muniain, MA; Navarro, MD; Pascual, A; Ríos, MJ; Rodríguez-Baño, J; Romero, L | 1 |
| Avlamis, A; Daikos, GL; Markogiannakis, A; Papaparaskevas, J; Papapareskevas, J; Petrikkos, G; Stefanakos, G; Zissis, NP | 1 |
| Drusano, GL; Lodise, TP; Lomaestro, B | 1 |
| Tucker, H; Wu, D | 1 |
| Bennett, KM; Dodds-Ashley, E; Hayward, TZ; Kaye, KS; Scarborough, JE; Sharpe, M; Vaslef, SN | 1 |
| Braga, AL; Burattini, MN; Jukemura, EM; Medeiros, EA; Pereira, CA | 1 |
| Akova, M; Altun, B; Gürkan Aydin, N; Hasçelik, G; Metan, G; Zarakolu, P | 1 |
| Dowzicky, M; Kuti, JL; Nicolau, DP | 1 |
| Barnaud, G; Chevrel, G; Dreyfuss, D; Eveillard, M; Meybeck, A; Mounier, R; Ricard, JD | 1 |
| Ernest, KD; Magnussen, CR; Sammartino, MT | 1 |
| Bassler, M; Becker, C; Daschner, FD; Just, HM | 1 |
| Betschel, S; Kreiswirth, B; Low, DE; Willey, BM | 1 |
| Sanders, CV | 1 |
| Spencer, RC | 1 |
| Georgieff, M; Konrad, F; Neumeister, B; Rommel, H; Wagner, R | 1 |
| Adhikari, M; Pillay, DG; Pillay, T; Sturm, AW | 1 |
| Mokaddas, E; Rotimi, VO; Sanyal, SC | 1 |
| Bianchi, C; Bonfiglio, G; Nicoletti, G; Stefani, S; Zollo, A | 1 |
| Grossenbacher, M; Imhof, E; Speich, R; Vogt, M; Zimmerli, W | 1 |
| Ambrosetti, P; Aymon, D; Bille, J; Chiolero, R; Cometta, A; Glauser, MP; Harbarth, S; Huber, O; Jaccard, C; Lew, D; Praz, G; Ricou, B; Romand, J; Schneider, R; Troillet, N; Zanetti, G | 1 |
| Birawska, I; Fuchs, J; Szulakowska, E | 1 |
| Rokosz, A; Sawicka-Grzelak, A | 1 |
| Corrado, OJ; Fawley, WN; Hawkey, PM; Settle, CD; Wilcox, MH | 1 |
| Lessing, MP; Stewart, BA | 1 |
| Bernstein, J; Joshi, M; Kuye, O; Solomkin, J; Wester, BA | 1 |
| Mokaddas, EM; Sanyal, SC | 1 |
| Miranda, E; Sader, HS; Sejas, L; Tosin, I | 1 |
| Bradley, SJ | 1 |
| Cross, JM; May, AK; McGwin, G; Melton, SM; Moser, SA; Rue, LW | 1 |
| Bolsoni, AP; Mendes, RE; Roland, RK; Sader, HS; Silbert, S | 1 |
| Mohammedi, I; Tigaud, S; Tournadre, JP | 1 |
| Coia, JE; Gillespie, TA; Hanson, MF; Johnson, PR; Notman, AW | 1 |
| O'Connell, M; Petros, AJ; Roberts, C; van Saene, HK; Wade, P | 1 |
| Allen, MC; Bradley, SJ; Goldstone, AH; Scott, GM; Sher, HA; Wilson, AL | 1 |
| Abi-Said, D; Bivins, C; Hachem, R; Hanna, H; Huaringa, A; Raad, I; Sukumaran, A; Thornby, J; Walsh, G; Whimbey, E | 1 |
| Alvarez-Lerma, F; Barcenilla, F; Insausti-Ordeñana, J; Jordá-Marcos, R; Maraví-Poma, E; Martínez-Pellús, A; Nava, J; Palomar, M; Torres-Martí, A | 1 |
| Akhan, S; Coskunkan, F; Tansel, O; Vahaboglu, H | 1 |
| Plosker, GL; Young, M | 1 |
| Harris, AD; Johnson, JA; Kaye, KS; Morris, G; Perencevich, E; Roghmann, MC | 1 |
| Cassone, M; Falcone, M; Paris, A; Pavoni, G; Pistella, E; Venditti, M | 1 |
| Farris, AG; Goffi, MB | 1 |
| Carrère-Debat, D; Coupry, A; Demingeon, G; Holzapfel, L; Jehl, F; Lyonnet, F; Miranda, P | 1 |
| Beaucaire, G; Beuscart, C; Caillaux, M; Chidiac, C; Karp, P; Leroy, O | 1 |
| Bercault, N; Demasure, M; Gueveler, C; Martin, P; Poisson, D | 1 |
| Lu, Z | 1 |
| Santi, F | 1 |
| Adachi, M; Fujimori, I; Kobayashi, Y; Sekita, T; Suzuki, Y; Tomii, M | 1 |
| Attisso, M; Bertrand, A; Beziau, H; Jonquet, O; Kassis, J; Perez, C; Pochet, I; Simeon De Buochberg, M | 1 |
| Heard, MC; Hemsell, DL; Hemsell, PG; Nobles, BJ | 1 |
| Amato, G; Anzivino, D; Bolletti-Censi, M; Covelli, I; Fortunato, A; Guarino, A; Gulletta, E; Lavitola, A; Nani, E; Spagnoletti, G | 1 |
| Cox, CE | 1 |
| Chen, HY; Williams, JD | 1 |
| Citron, DM; Goldstein, EJ | 1 |
6 review(s) available for piperacillin and Health Care Associated Infection
| Article | Year |
|---|---|
The use of piperacillin-tazobactam in neonatal and paediatric patients.
Topics: Anti-Bacterial Agents; Child; Clinical Trials as Topic; Cross Infection; Humans; Infant, Newborn; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2009 |
Antimicrobial resistance in gram-positive bacteria.
Topics: Animals; beta-Lactamase Inhibitors; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Combinations; Drug Resistance, Bacterial; Enterococcus faecalis; Gastrointestinal Tract; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Methicillin Resistance; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin Resistance | 2006 |
Enterococcis: pathogens of the 90s.
Topics: Abdominal Abscess; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Enterococcus; Gram-Positive Bacterial Infections; Humans; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin | 1994 |
Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
Topics: Bacterial Infections; Cost-Benefit Analysis; Cross Infection; Drug Therapy, Combination; Drug Tolerance; Economics, Pharmaceutical; Hospitalization; Humans; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2001 |
[Piperacillin-tazobactam in the treatment of severe nosocomial infections].
Topics: Bacteria; beta-Lactamase Inhibitors; Clinical Trials as Topic; Costs and Cost Analysis; Cross Infection; Drug Combinations; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Pneumonia; Tazobactam | 2002 |
[Clinical experience with piperacillin in the prophylaxis of post-operative infections].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Cross Infection; Female; Humans; Male; Middle Aged; Piperacillin; Postoperative Complications; Premedication | 1990 |
25 trial(s) available for piperacillin and Health Care Associated Infection
| Article | Year |
|---|---|
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections | 2017 |
[Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged vs. regular infusion].
Topics: Aged; Anti-Bacterial Agents; Cross Infection; Drug Administration Schedule; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Prospective Studies | 2013 |
Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Load; Cross Infection; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Remission Induction; Spain; Time Factors; Treatment Outcome; Young Adult | 2016 |
Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; China; Chromatography, High Pressure Liquid; Costs and Cost Analysis; Critical Illness; Cross Infection; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Pneumonia, Bacterial; Treatment Outcome; Young Adult | 2017 |
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Cross Infection; Doripenem; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Prospective Studies; Tazobactam; Treatment Outcome | 2008 |
Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefepime; Cephalosporins; Cohort Studies; Cross Infection; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, Teaching; Hospitals, Urban; Humans; Infusions, Intravenous; Intensive Care Units; Length of Stay; Male; Meropenem; Middle Aged; Missouri; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2013 |
Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cross Infection; Female; Humans; Japan; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Prospective Studies; Statistics, Nonparametric; Thienamycins; Treatment Outcome | 2013 |
Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.
Topics: Algorithms; Computer Simulation; Cross Infection; Drug Interactions; Enzyme Inhibitors; Half-Life; Humans; Models, Biological; Monte Carlo Method; Penicillanic Acid; Penicillins; Piperacillin; Population; Tazobactam | 2004 |
Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
Topics: Adult; Aged; Anti-Bacterial Agents; Cholangitis; Community-Acquired Infections; Cross Infection; Drug Administration Schedule; Female; Fever of Unknown Origin; Hospitalization; Humans; Infections; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Prospective Studies; Treatment Outcome; Urinary Tract Infections | 2005 |
Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia.
Topics: Anti-Bacterial Agents; Cilastatin; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Protease Inhibitors; Tazobactam; Tobramycin; Treatment Outcome | 2006 |
Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study.
Topics: Adult; Cilastatin; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Penicillanic Acid; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2006 |
Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
Topics: Abdominal Abscess; Administration, Oral; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Appendicitis; Aza Compounds; Bacterial Infections; Cross Infection; Double-Blind Method; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Injections, Intravenous; Intestinal Perforation; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Quinolines; Safety; Stomach Rupture; Treatment Outcome | 2006 |
Piperacillin/tazobactam in the treatment of community-acquired and nosocomial respiratory tract infections: a review.
Topics: Adult; Aged; Amikacin; beta-Lactamase Inhibitors; Community-Acquired Infections; Cross Infection; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Tazobactam | 1994 |
Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia.
Topics: Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Community-Acquired Infections; Cross Infection; Drug Therapy, Combination; Female; Gentamicins; Humans; Male; Middle Aged; Netilmicin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Treatment Outcome | 1998 |
Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
Topics: Acute Disease; Adult; Aged; Cilastatin; Cilastatin, Imipenem Drug Combination; Cross Infection; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas Infections; Tazobactam | 1998 |
Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam.
Topics: Aged; beta-Lactamase Inhibitors; Cefotaxime; Clostridioides difficile; Cross Infection; Cross-Over Studies; Diarrhea; Drug Combinations; Enterocolitis, Pseudomembranous; Enzyme Inhibitors; Female; Humans; Male; Opportunistic Infections; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 1998 |
Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ceftazidime; Cross Infection; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperacillin; Respiratory Tract Infections; Tobramycin | 1999 |
The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ceftazidime; Cross Infection; Drug Resistance, Microbial; Enterococcus; Female; Glycopeptides; Gram-Positive Bacterial Infections; Hematology; Hospital Units; Humans; Infection Control; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 1999 |
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study.
Topics: Aged; Amikacin; Aztreonam; Chi-Square Distribution; Clindamycin; Cross Infection; Drug Therapy, Combination; Humans; Middle Aged; Neoplasms; Opportunistic Infections; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Postoperative Complications; Prognosis; Prospective Studies; Tazobactam | 2001 |
Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
Topics: Aged; Amikacin; Ceftazidime; Cephalosporins; Critical Care; Cross Infection; Drug Therapy, Combination; Female; Hospital Mortality; Hospitals, Teaching; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Proportional Hazards Models; Prospective Studies; Spain; Survival Analysis; Treatment Outcome | 2001 |
[Diffusion of piperacillin into the sinuses of patients with nosocomial sinusitis].
Topics: Adult; Aged; Biological Transport; Cross Infection; Female; Humans; Injections, Intravenous; Male; Maxillary Sinusitis; Middle Aged; Paranasal Sinuses; Piperacillin; Respiration, Artificial | 1991 |
Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections.
Topics: Adult; Aged; Amikacin; Bacterial Infections; Cefotaxime; Ceftazidime; Cross Infection; Drug Administration Schedule; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Male; Middle Aged; Ofloxacin; Piperacillin; Prospective Studies | 1991 |
[Clinical comparative study of intravenous piperacillin sodium or injection of scutellaria compound in patients with pulmonary infection].
Topics: Adult; Aged; Aged, 80 and over; Cross Infection; Drugs, Chinese Herbal; Female; Humans; Injections, Intravenous; Male; Middle Aged; Piperacillin; Pneumonia | 1990 |
Piperacillin and a combination of clindamycin and gentamicin for the treatment of hospital and community acquired acute pelvic infections including pelvic abscess.
Topics: Abscess; Adult; Bacterial Infections; Clindamycin; Clinical Trials as Topic; Costs and Cost Analysis; Cross Infection; Drug Therapy, Combination; Female; Gentamicins; Humans; Pelvic Inflammatory Disease; Piperacillin; Random Allocation; Salpingitis | 1987 |
Timentin versus piperacillin in the treatment of hospitalized patients with urinary tract infections.
Topics: Adult; Aged; Bacteria; Bacterial Infections; Clavulanic Acids; Cross Infection; Drug Combinations; Drug Evaluation; Female; Humans; Male; Middle Aged; Penicillin Resistance; Penicillins; Piperacillin; Sepsis; Ticarcillin; Urinary Tract Infections | 1986 |
126 other study(ies) available for piperacillin and Health Care Associated Infection
| Article | Year |
|---|---|
Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Isoelectric Focusing; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Netherlands; Plasmids | 2007 |
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Middle Aged; Portugal | 2007 |
Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cross Infection; Humans; Italy; Microbial Sensitivity Tests | 2007 |
Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
Topics: Bacteremia; Community-Acquired Infections; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Enterobacteriaceae Infections; Gene Transfer, Horizontal; Humans; Infectious Disease Transmission, Professional-to-Patient; Integrons; Microbial Sensitivity Tests; Nucleic Acid Amplification Techniques; Polymerase Chain Reaction; Prospective Studies; Risk Factors; Sequence Analysis, DNA; Treatment Outcome | 2007 |
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
Topics: Acinetobacter; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Brazil; Codon, Terminator; Cross Infection; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Genes, Bacterial; Hospitals; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Open Reading Frames; Plasmids; Pseudomonas putida; Transcription, Genetic | 2007 |
Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
Topics: Acinetobacter; Acinetobacter baumannii; Acinetobacter Infections; Bacterial Proteins; beta-Lactamases; Cross Infection; Humans; Plasmids; Portugal | 2007 |
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Chromosomes, Bacterial; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Integrons; Molecular Epidemiology; Molecular Sequence Data; Mutation; Plasmids; Polymerase Chain Reaction; Porins; Pseudomonas aeruginosa; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Spain | 2007 |
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
Topics: Bacterial Proteins; beta-Lactamases; Cross Infection; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Mexico; Models, Genetic; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Genetic; Turkey | 2008 |
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; Blood; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Taiwan | 2008 |
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Cross Infection; Enterocolitis, Pseudomembranous; Glycosides; Humans; In Vitro Techniques; Microbial Sensitivity Tests | 2008 |
A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Conjugation, Genetic; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Hospitals, University; Humans; Imipenem; Lebanon; Molecular Epidemiology; Molecular Sequence Data; Plasmids | 2008 |
Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
Topics: Anti-Bacterial Agents; Base Sequence; beta-Lactamases; Colistin; Cross Infection; Humans; Molecular Sequence Data; Pseudomonas aeruginosa | 2009 |
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
Topics: Belgium; beta-Lactamases; Cephalosporinase; Cephalosporins; Cross Infection; Escherichia coli; Genes, Bacterial; Humans; Kinetics; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Cross Infection; Humans; Intensive Care Units; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Antimicrobial use among paediatric inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program, 2017/2018.
Topics: Adult; Anti-Infective Agents; Canada; Cefazolin; Ceftriaxone; Child; Cross Infection; Hospitals; Humans; Infant, Newborn; Inpatients; Piperacillin; Tazobactam | 2023 |
Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Cross Infection; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Brain Exposure to Piperacillin in Acute Hemorrhagic Stroke Patients Assessed by Cerebral Microdialysis and Population Pharmacokinetics.
Topics: Anti-Bacterial Agents; Brain; Cross Infection; Female; Hemorrhagic Stroke; Humans; Male; Microdialysis; Penicillanic Acid; Piperacillin; Retrospective Studies | 2020 |
Severe bleeding caused by piperacillin/tazobactam-induced platelet dysfunction
.
Topics: Aged; Anti-Bacterial Agents; Blood Platelet Disorders; Cross Infection; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated | 2020 |
A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Cross Infection; Febrile Neutropenia; Guidelines as Topic; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Teicoplanin; Tertiary Care Centers; Treatment Outcome; Turkey; Vancomycin | 2017 |
Use of Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin-Tazobactam Safety in Infants.
Topics: Anti-Bacterial Agents; Area Under Curve; Cross Infection; Electronic Health Records; Female; Humans; Infant; Infant, Newborn; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2017 |
Comparison of the therapeutic efficacy of fluoroquinolone and non-fluoroquinolone treatment in patients with Elizabethkingia meningoseptica bacteraemia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Chryseobacterium; Cross Infection; Female; Flavobacteriaceae Infections; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Taiwan; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
First report of cavitary pneumonia due to community-acquired Acinetobacter pittii, study of virulence and overview of pathogenesis and treatment.
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Animals; Caenorhabditis elegans; Community-Acquired Infections; Cross Infection; Female; France; Humans; Middle Aged; Multilocus Sequence Typing; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Virulence | 2017 |
Clinical Outcome and Antimicrobial Therapeutic Drug Monitoring for the Treatment of Infections in Acute Burn Patients.
Topics: Acinetobacter Infections; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Burns; Child; Child, Preschool; Cross Infection; Drug Monitoring; Female; Humans; Imipenem; Infant; Intensive Care Units; Male; Meropenem; Middle Aged; Piperacillin; Pneumonia; Prognosis; Tertiary Care Centers; Thienamycins; Urinary Tract Infections; Vancomycin; Young Adult | 2017 |
[Piperacillin/Tazobactam Shortage: Central Restriction and Alternative Recommendations as Effective Antibiotic-Stewardship Intervention at a Maximal Care Hospital].
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Cross Infection; Hospitals; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Practice Guidelines as Topic | 2018 |
[Retrospective Analysis of Factors Decreasing the Efficacy of Tazobactam/Piperacillin for Pneumonia in Elderly Patients].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Chronic Disease; Cross Infection; Female; Hospitals; Humans; Male; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Respiratory Tract Diseases; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2018 |
Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program,
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Colistin; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; United States | 2018 |
[Analysis of the distribution characteristics and drug resistance of non-fermenting bacterial infection in intensive care unit from 2009 to 2015]
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cefoperazone; Cephalosporins; Cross Infection; Drug Resistance; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Retrospective Studies; Thienamycins | 2016 |
A comparison of Sensititre™ Anaerobe MIC plate with ATB ANA® test for the routine susceptibility testing of common anaerobe pathogens.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Cross Infection; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Penicillins; Piperacillin; Switzerland | 2018 |
In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefoperazone; Ceftazidime; China; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Outbreak of ampicillin/piperacillin-resistant Klebsiella pneumoniae in a neonatal intensive care unit (NICU): investigation and control measures.
Topics: Ampicillin; Anti-Bacterial Agents; Cross Infection; Disease Outbreaks; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Female; Humans; Infant, Newborn; Infant, Premature; Infection Control; Intensive Care Units, Neonatal; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Piperacillin | 2013 |
The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
Topics: Anti-Bacterial Agents; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 2013 |
Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; Cilastatin; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Minocycline; Piperacillin; Sulbactam; Tigecycline; Treatment Outcome | 2013 |
Drug resistance patterns of bacteria isolated from patients with nosocomial pneumonia at Tehran hospitals during 2009-2011.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ceftriaxone; Cross Infection; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hospitals; Humans; Iran; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Polymyxin B; Prevalence; Pseudomonas aeruginosa; Respiratory Tract Infections; Sputum; Staphylococcus aureus | 2013 |
Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cross Infection; Female; Hospitalization; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Retrospective Studies; Sputum; Thienamycins | 2013 |
Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia from respiratory tract in a regional hospital.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Case-Control Studies; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Female; Gram-Negative Bacterial Infections; Hospitals; Humans; Levofloxacin; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Respiratory Tract Infections; Risk Factors; Sputum; Stenotrophomonas maltophilia | 2015 |
In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Carbapenems; Cefoperazone; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Tigecycline | 2013 |
Epidemiological and bacteriological profiles in children with burns.
Topics: Anti-Bacterial Agents; Burns; Child; Child, Preschool; Cohort Studies; Cross Infection; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Female; Gentamicins; Humans; Male; Oxacillin; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Staphylococcal Infections; Staphylococcus aureus; Wound Infection | 2014 |
Clinical manifestations and prognostic factors of Morganella morganii bacteremia.
Topics: Age Factors; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Female; Gentamicins; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Morganella morganii; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; Taiwan | 2015 |
Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Cross Infection; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Porins; Pseudomonas aeruginosa; Pseudomonas Infections | 2014 |
Nephrotoxicity induced by piperacillin–tazobactam in late elderly Japanese patients with nursing and healthcare associated pneumonia.
Topics: Aged; Aged, 80 and over; Aging; Anti-Bacterial Agents; Asian People; Cross Infection; Female; Humans; Kidney Diseases; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial | 2014 |
Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008-2013 at a tertiary hospital in Shanghai, China.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ceftazidime; China; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Utilization Review; Escherichia coli; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Inpatients; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Tertiary Care Centers | 2015 |
Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Catheter-Related Infections; Ceftazidime; Community-Acquired Infections; Cross Infection; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Fluoroquinolones; Hospitalization; Hospitals, University; Humans; Immunocompromised Host; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prostatitis; Recurrence; Retrospective Studies; Risk Factors; Urinary Tract Infections; Young Adult | 2015 |
Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
Topics: Anti-Bacterial Agents; Body Weight; Cross Infection; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2016 |
Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Community-Acquired Infections; Cross Infection; Female; Hospital Mortality; Humans; Male; Middle Aged; Needs Assessment; Organizational Policy; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Prognosis; Pseudomonas Infections | 2015 |
Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
Topics: Adult; Anti-Infective Agents; beta-Lactamases; Cefepime; Cephalosporins; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; United States | 2015 |
Retrospective cohort study of inappropriate piperacillin-tazobactam use for lower respiratory tract and skin and soft tissue infections: Opportunities for antimicrobial stewardship.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Cohort Studies; Community-Acquired Infections; Cross Infection; Drug Utilization; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Retrospective Studies; Skin Diseases, Infectious; Soft Tissue Infections | 2015 |
Understanding Gram-negative Central Line-Associated Blood Stream Infection in a Surgical Trauma ICU.
Topics: Adult; Aged; Bacteremia; Catheter-Related Infections; Catheterization, Central Venous; Cohort Studies; Comprehension; Cross Infection; Female; Follow-Up Studies; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Incidence; Intensive Care Units; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Assessment; Survival Rate; Tertiary Care Centers; Treatment Outcome; Urban Population; Virginia | 2015 |
A Fatal Case of Nosocomial Legionnaires' Disease: Implications From an Extensive Environmental Investigation and Isolation of the Bacterium From Blood Culture.
Topics: Cross Infection; Environmental Exposure; Equipment Contamination; Fatal Outcome; Female; Humans; Italy; Legionella pneumophila; Legionnaires' Disease; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2015 |
Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoxitin; China; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Gene Expression; Humans; Imipenem; Intraabdominal Infections; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2016 |
Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Japan; Klebsiella Infections; Klebsiella oxytoca; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Penicillanic Acid; Piperacillin; Tazobactam | 2015 |
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infection Control in an Institutional Setting.
Topics: Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Cross Infection; Enterococcus faecium; Escherichia coli; Escherichia coli Infections; Genome, Bacterial; Gram-Positive Bacterial Infections; High-Throughput Nucleotide Sequencing; Humans; Infection Control; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; Staphylococcal Infections; Vancomycin-Resistant Enterococci | 2016 |
Prevalence and antimicrobial susceptibility of Acinetobacter spp. isolated from meat.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Animals; Anti-Bacterial Agents; Cattle; Ceftazidime; Chickens; Ciprofloxacin; Cross Infection; DNA-Directed RNA Polymerases; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Red Meat; Sulbactam; Swine; Trimethoprim, Sulfamethoxazole Drug Combination | 2017 |
Risk factors associated with fluoroquinolone-resistant enterococcal urinary tract infections in a tertiary care university hospital in north India.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Enterococcus; Female; Fluoroquinolones; Hospitals, University; Humans; India; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pregnancy; Risk Factors; Tertiary Care Centers; Urinary Tract Infections | 2016 |
Broad-spectrum antibiotics in Norwegian hospitals.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cephalosporins; Cross Infection; Cross-Sectional Studies; Drug Prescriptions; Drug Resistance, Bacterial; Drug Utilization Review; Guideline Adherence; Hospitals; Humans; Norway; Piperacillin; Quinolones; Respiratory Tract Infections | 2017 |
Comparison of the effect of ciprofloxacin and Tazocin on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Ciprofloxacin; Cross Infection; Data Interpretation, Statistical; Drug Combinations; Electrophoresis, Gel, Pulsed-Field; Hand Disinfection; Hygiene; Intensive Care Units; Methicillin-Resistant Staphylococcus aureus; Penicillanic Acid; Personnel, Hospital; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcal Infections; Tazobactam | 2008 |
Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients.
Topics: Adult; Cephalosporins; Critical Illness; Cross Infection; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genes, Viral; Genotype; Humans; Intensive Care Units; Male; Pharynx; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Rectum; Respiratory Mucosa | 2009 |
Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Case-Control Studies; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Imipenem; Length of Stay; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Vancomycin | 2008 |
First identification of class A carbapenemase-producing Klebsiella pneumoniae in the Republic of Ireland.
Topics: Bacterial Proteins; beta-Lactamases; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Ireland; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Tazobactam | 2009 |
Efficacy of intravenous infusion of doripenem.
Topics: Carbapenems; Cross Infection; Doripenem; Humans; Imipenem; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated | 2009 |
Distribution of different carbapenem resistant clones of Acinetobacter baumannii in Tehran hospitals.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefotaxime; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Hospitals; Humans; Imipenem; Iran; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2009 |
Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.
Topics: Area Under Curve; Bayes Theorem; Cross Infection; Drug Combinations; Female; Hospitalization; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Pneumococcal; Reproducibility of Results; Tazobactam; United States; United States Food and Drug Administration | 2010 |
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia.
Topics: Acinetobacter Infections; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Colistin; Cross Infection; Europe; Female; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Piperacillin; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Quinolones; Respiration, Artificial; Severity of Illness Index; Treatment Outcome | 2011 |
oprM as a new target for reversion of multidrug resistance in Pseudomonas aeruginosa by antisense phosphorothioate oligodeoxynucleotides.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Cross Infection; Dose-Response Relationship, Drug; Drug Carriers; Drug Resistance, Multiple, Bacterial; Gene Expression; Humans; Liposomes; Membrane Transport Proteins; Microbial Sensitivity Tests; Oligodeoxyribonucleotides, Antisense; Piperacillin; Polyethyleneimine; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Anti-Bacterial Agents; Catheters; Ceftazidime; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Imipenem; Male; Middle Aged; Piperacillin; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Republic of Korea; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2011 |
The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey.
Topics: Acinetobacter; Anti-Bacterial Agents; Cefepime; Ceftazidime; Ceftriaxone; Cephalosporins; Cost Savings; Cross Infection; Drug Costs; Drug Prescriptions; Drug Resistance, Bacterial; Drug Utilization; Escherichia; Health Policy; Hospitals; Humans; Imipenem; Klebsiella; Meropenem; Methicillin Resistance; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas; Staphylococcus aureus; Teicoplanin; Thienamycins; Turkey; Vancomycin | 2011 |
Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacteremia; Cross Infection; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2012 |
A rare cause of bacteremia in a pediatric patient with Down syndrome: Sphingomonas paucimobilis.
Topics: Bacteremia; Cross Infection; Down Syndrome; Gram-Negative Bacterial Infections; Humans; Infant; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Sphingomonas | 2011 |
A 9-Year retrospective review of antibiotic cycling in a surgical intensive care unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Critical Care; Cross Infection; Drug Combinations; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Infection Control; Klebsiella Infections; Klebsiella pneumoniae; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Surgical Wound Infection | 2012 |
Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coli.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2016 |
Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
Topics: Adult; Anti-Bacterial Agents; Cross Infection; Drug Administration Schedule; Female; Hospitalization; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Young Adult | 2012 |
The effect of antibiotic rotation on colonization with antibiotic-resistant bacilli in a neonatal intensive care unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Cross Infection; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Gentamicins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Microbial Sensitivity Tests; Penicillanic Acid; Pharynx; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rectum | 2002 |
Antibiotic therapy of ventilator-associated pneumonia: in search of the magic bullet.
Topics: Cross Infection; Drug Therapy, Combination; Humans; Intensive Care Units; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Respiration, Artificial; Treatment Outcome | 2003 |
Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; California; Cross Infection; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Intensive Care Units; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Proportional Hazards Models; Prospective Studies; Respiration, Artificial; Survival Rate; Treatment Outcome | 2003 |
[Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
Topics: Anti-Bacterial Agents; Cefoperazone; Cross Infection; Drug Resistance, Microbial; Gram-Negative Bacteria; Humans; Intensive Care Units; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Sulbactam | 2003 |
Nosocomial bacteremia and catheter infection by Bacillus cereus in an immunocompetent patient.
Topics: Aged; Bacillaceae Infections; Bacillus cereus; Bacteremia; Catheterization, Central Venous; Catheters, Indwelling; Cross Infection; Digestive System Surgical Procedures; Drug Therapy, Combination; Humans; Immunocompetence; Male; Penicillanic Acid; Piperacillin; Tazobactam | 2003 |
Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients.
Topics: Anti-Bacterial Agents; Cross Infection; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2003 |
Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated mice.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Candida glabrata; Candidiasis; Community-Acquired Infections; Cross Infection; DNA, Bacterial; DNA, Fungal; Drug Synergism; Enterococcus faecium; Feces; Female; Gram-Positive Bacterial Infections; Klebsiella Infections; Klebsiella pneumoniae; Mice; Piperacillin; Polymerase Chain Reaction | 2003 |
Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy.
Topics: Anti-Bacterial Agents; Ceftazidime; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Infant, Newborn; Infection Control; Israel; Klebsiella Infections; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2003 |
Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance.
Topics: Anti-Bacterial Agents; Argentina; Cephalosporin Resistance; Cephalosporins; Cross Infection; Drug Prescriptions; Drug Utilization; Humans; Infection Control; Klebsiella Infections; Klebsiella pneumoniae; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2004 |
Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin.
Topics: Clostridioides difficile; Cross Infection; Diarrhea; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Humans; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; United States | 2004 |
Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia.
Topics: Cross Infection; Epithelial Cells; Female; Humans; Intensive Care Units; Lung; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Prospective Studies; Respiration, Artificial | 2004 |
Safety evaluation of piperacillin/tazobactam in very low birth weight infants.
Topics: Anti-Bacterial Agents; Bacteremia; Cross Infection; Drug Therapy, Combination; Enterocolitis, Necrotizing; Female; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Infant, Very Low Birth Weight; Male; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2004 |
Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci.
Topics: Anti-Bacterial Agents; Carrier State; Clavulanic Acids; Cross Infection; Enterococcus faecium; Female; Formularies, Hospital as Topic; Gastrointestinal Tract; Humans; Intensive Care Units; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Risk Factors; Ticarcillin; Time Factors; Vancomycin Resistance | 2004 |
[Microbiological diagnostic and antibiotic management of community aquired and nosocomial pneumonias in intensive care units in Germany].
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Bronchoalveolar Lavage Fluid; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Enzyme Inhibitors; Germany; Guidelines as Topic; Humans; Intensive Care Units; Penicillins; Piperacillin; Pneumonia; Population Surveillance; Respiration, Artificial; Surveys and Questionnaires | 2005 |
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Thienamycins | 2005 |
Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.
Topics: Anti-Infective Agents; Candida glabrata; Candidiasis; Case-Control Studies; Cross Infection; Female; Fluconazole; Fungemia; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Factors; Vancomycin | 2005 |
[Postoperative pneumonia: nosocomial, predictable, iatrogenic, preventable or not?].
Topics: Alcoholism; Amoxicillin-Potassium Clavulanate Combination; Antibiotic Prophylaxis; Carcinoma, Squamous Cell; Ciprofloxacin; Cross Infection; Disease Susceptibility; Fatal Outcome; Humans; Iatrogenic Disease; Immunocompromised Host; Liver Cirrhosis, Alcoholic; Male; Malnutrition; Malpractice; Middle Aged; Mouth; Neck Dissection; Neoplasm Recurrence, Local; Oxygen; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Postoperative Complications; Pulmonary Disease, Chronic Obstructive; Risk Factors; Smoking; Tongue Neoplasms | 2006 |
Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Cefoperazone; Clavulanic Acids; Cross Infection; Gram-Negative Bacteria; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Ticarcillin | 2005 |
Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections.
Topics: Anti-Bacterial Agents; California; Clostridioides difficile; Cross Infection; Drug Prescriptions; Drug Utilization; Enterococcus; Enterocolitis, Pseudomembranous; Gram-Positive Bacterial Infections; Humans; Length of Stay; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; United States; Vancomycin Resistance | 2006 |
Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cephalosporins; Cohort Studies; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2006 |
Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospita
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporin Resistance; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Enterobacteriaceae Infections; Enzyme Inhibitors; Escherichia coli; Greece; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Prospective Studies; Tazobactam; Time Factors | 2007 |
Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; APACHE; beta-Lactams; Cohort Studies; Critical Illness; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Retrospective Studies | 2007 |
Appropriate comparators for alternate dosing strategies.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Monte Carlo Method; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Risk Assessment; Tazobactam; Treatment Outcome | 2007 |
Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Clinical Protocols; Critical Care; Cross Infection; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Incidence; Intensive Care Units; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Probability; Retrospective Studies; Sensitivity and Specificity; Tazobactam; Treatment Outcome | 2007 |
Control of multi-resistant bacteria and ventilator-associated pneumonia: is it possible with changes in antibiotics?
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Hospitals, University; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Prospective Studies; Tazobactam | 2007 |
[The frequency of PER-1 type extended spectrum beta-lactamases in nosocomial isolates of Pseudomonas aeruginosa].
Topics: Anti-Bacterial Agents; beta-Lactamases; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin | 2007 |
A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics.
Topics: Anti-Bacterial Agents; Cross Infection; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Minocycline; Models, Biological; Monte Carlo Method; Ofloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Tigecycline | 2008 |
Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cohort Studies; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; France; Humans; Incidence; Intensive Care Units; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Treatment Outcome | 2008 |
Aminoglycoside-resistant gram-negative bacilli in a community hospital: comparative in vitro activity of cefotaxime, moxalactam, cefoperazone, and piperacillin.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteria; Cefoperazone; Cefotaxime; Cephalosporins; Cephamycins; Cross Infection; Humans; Moxalactam; Penicillin Resistance; Penicillins; Piperacillin | 1982 |
In vitro combination effects of cefotetan with four aminoglycosides, piperacillin and mezlocillin on gram-positive and gram-negative nosocomial bacteria.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cefotetan; Cephamycins; Cross Infection; Drug Interactions; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Mezlocillin; Microbial Sensitivity Tests; Piperacillin | 1984 |
Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cefpirome; Ceftazidime; Ceftriaxone; Cephalosporins; Cross Infection; Drug Resistance, Microbial; Europe; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospital Units; Humans; Imipenem; Intensive Care Units; Microbial Sensitivity Tests; Piperacillin; Prevalence | 1993 |
Studies on drug monitoring in thrice and once daily treatment with aminoglycosides.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cefotaxime; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fosfomycin; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Intensive Care Units; Male; Metabolic Clearance Rate; Metronidazole; Middle Aged; Netilmicin; Piperacillin; Respiration, Artificial; Staphylococcal Infections; Teicoplanin | 1993 |
Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
Topics: Anti-Infective Agents; beta-Lactamase Inhibitors; Cilastatin; Ciprofloxacin; Cross Infection; Drug Combinations; Drug Resistance, Microbial; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Imipenem; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Protease Inhibitors; Retrospective Studies; Tazobactam; Thienamycins | 1998 |
In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.
Topics: Burns; Cross Infection; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1998 |
Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cross Infection; Enzyme Inhibitors; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; Italy; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1998 |
[Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
Topics: beta-Lactamase Inhibitors; Body Fluids; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Species Specificity; Tazobactam | 1998 |
[Susceptibility of clinical strains of gram-positive bacteria to selected beta-lactam antibiotics].
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Clavulanic Acids; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Species Specificity; Thienamycins; Ticarcillin | 1998 |
A hospital outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Klebsiella Infections; Klebsiella pneumoniae; Penicillanic Acid; Penicillin Resistance; Piperacillin; Tazobactam | 1999 |
Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.
Topics: Carbapenems; Cross Infection; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Incidence; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Risk Factors | 1999 |
Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Clavulanic Acid; Cross Infection; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam; Ticarcillin | 2000 |
Control of glycopeptide-resistant enterococci in an oncology unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cohort Studies; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Fever; Glycopeptides; Humans; Infection Control; Neoplasms; Neutropenia; Oncology Service, Hospital; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2000 |
Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit.
Topics: Burn Units; Cephalosporins; Clinical Protocols; Cross Infection; Drug Utilization; Enterococcus; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Methicillin Resistance; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Staphylococcal Infections; Staphylococcus aureus; Tazobactam; Vancomycin; Vancomycin Resistance; Wounds and Injuries | 2000 |
In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Topics: Bacteria; Bacterial Infections; beta-Lactams; Brazil; Cross Infection; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Hospitals, University; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2000 |
Emergence of piperacillin/tazobactam-resistant Escherichia coli.
Topics: beta-Lactamase Inhibitors; Communicable Diseases, Emerging; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli Infections; France; Humans; Infection Control; Intensive Care Units; Patient Selection; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 2000 |
Eradication of a resistant Pseudomonas aeruginosa strain after a cluster of infections in a hematology/oncology unit.
Topics: Bacteremia; Cross Infection; Drug Resistance, Multiple; Enzyme Inhibitors; Hospitals, General; Humans; Infection Control; Intensive Care Units; Microbial Sensitivity Tests; Oncology Service, Hospital; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Sanitary Engineering; Scotland; Species Specificity; Sputum; Tazobactam | 2000 |
Systemic antibiotics fail to clear multidrug-resistant Klebsiella from a pediatric ICU.
Topics: Amikacin; beta-Lactamase Inhibitors; Cohort Studies; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Infant; Intensive Care Units, Pediatric; Klebsiella; Klebsiella Infections; Male; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 2001 |
Conjugative resistance to tazobactam plus piperacillin among extended-spectrum beta-lactamase-producing nosocomial Klebsiella pneumoniae.
Topics: Base Sequence; beta-Lactam Resistance; beta-Lactamases; Cross Infection; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Klebsiella Infections; Klebsiella pneumoniae; Molecular Sequence Data; Penicillanic Acid; Penicillins; Piperacillin; Polymerase Chain Reaction; Tazobactam; Turkey | 2001 |
Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.
Topics: Adult; Case-Control Studies; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas Infections; Regression Analysis; Risk Factors; Tazobactam | 2002 |
[Piperacillin: comparison of antibacterial activity in vitro during the triennium 1986-88 versus the biennium 1981-82].
Topics: Anti-Bacterial Agents; Bacteria; Cross Infection; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Piperacillin | 1992 |
[Changes in resistance of Pseudomonas aeruginosa to beta-lactams in a general intensive care unit over a three-year period. Role of piperacillin].
Topics: Cefsulodin; Ceftazidime; Cross Infection; Drug Resistance, Microbial; Female; Humans; Imipenem; Intensive Care Units; Male; Middle Aged; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin | 1991 |
[Clinical studies on septicemia and infective endocarditis encountered between 1985-1986].
Topics: Adult; Aged; Aged, 80 and over; Cefmetazole; Cross Infection; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Humans; Male; Middle Aged; Piperacillin; Prognosis; Sepsis | 1989 |
[In vitro bactericidal effect of a piperacillin-pefloxacin combination against isolated strains of nosocomial pneumopathies in intensive care].
Topics: Cross Infection; Drug Synergism; Drug Therapy, Combination; Microbial Sensitivity Tests; Pefloxacin; Piperacillin | 1989 |
[Evaluation of the in vitro activity of aztreonam on 1990 gram-negative bacterial strains recently isolated in Campania hospitals].
Topics: Aztreonam; Cefotaxime; Ceftazidime; Cross Infection; Gentamicins; Gram-Negative Bacteria; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Piperacillin; Structure-Activity Relationship | 1986 |
The place of temocillin in the treatment of hospital infections.
Topics: beta-Lactamases; Carbenicillin; Chromosomes, Bacterial; Cross Infection; Enterobacteriaceae Infections; Gram-Negative Bacteria; Humans; Mezlocillin; Penicillin Resistance; Penicillins; Piperacillin; Plasmids | 1985 |
Comparative in vitro activity of cefbuperazone against anaerobic bacteria isolated from community hospitals.
Topics: Bacteria, Anaerobic; Cefoxitin; Cephamycins; Clindamycin; Cross Infection; Hospitals, Community; Humans; Microbial Sensitivity Tests; Moxalactam; Piperacillin | 1985 |